Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
1. Presenters reported significant efficacy of sotagliflozin in older adults. 2. Sotagliflozin reduces heart failure and MACE in diverse age groups. 3. Data from 12,000 participants support sotagliflozin's effectiveness. 4. Future research may explore effects in heart failure patients with preserved ejection fraction. 5. Lexicon Pharmaceuticals continues to expand its drug pipeline.